5 Top Weekly NASDAQ Biotech Stocks: vTv Increases 163 Percent
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
Your trusted source for investing success
Your trusted source for investing success
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
Novelion Therapeutics, EyePoint Pharmaceuticals, CytRx, Viking Therapeutics and AVEO Pharmaceuticals were last week’s top gainers.
Cardiome, Avid, XBiotech, Fennec and Compugen were last week’s five top-gaining NASDAQ biotech stocks. See what moved their share prices.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that its collaborator, Sanofi, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for use in combination with insulin therapy
Second Sight, Juniper, Athersys, Aptose and ArQule were last week’s five top-gaining NASDAQ biotech stocks. See what moved their share prices.
Medtronic (NYSE:MDT), the global leader in medical technology, services and solutions, today announced it received U.S. Food and Drug Administration (FDA) approval for its Guardian(TM) Connect continuous glucose monitoring (CGM) system, for people with diabetes ages 14 to 75 years. The Guardian Connect system is the first smart standalone CGM
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
This diabetes care focused company is the only to manufacture an insulin pump with a touchscreen and is now hoping to break into the Canadian diabetes market with a Health Canada medical device license. The company anticipates launching the pump in the second half of 2018 if the application is
The bigger problem is when these attacks are against healthcare companies carrying millions of patients personal information; the attacks can lead to postponed surgeries, leaking information or even shutting down entire computer networks in hospitals.
Medtronic (NYSE:MDT), the global leader in medical technology, services and solutions, today introduced the MiniMed(TM) Mio(TM) Advance infusion set. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives patients a simpler, faster and more convenient set change with fewer steps.
As
Many companies are taking advantage of partnerships and M&As, whereas others are looking to maximize their own sales by solely developing products.
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
Catalyst Biosciences, Adverum Biotechnologies, MannKind, Galectin Therapeutics and Aptose Biosciences topped last week’s NASDAQ biotech stock list.
Here we take a look at the top 10 largest pharmaceutical companies dominating the industry to give investors insight.
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces the United States Patent and Trademark Office (“USPTO”) has granted patent number 9,839,612 B2 for the use of DehydraTECHTM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients (“APIs”)
MannKind announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza (insulin human) inhalation powder in Brazil.
ALR Technologies announced the FDA granted clearance for an innovative insulin dose adjustment feature of the ALRT diabetes management system.
ALR Technologies announced the US Food and Drug Administration granted clearance for their innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system.
By Shelly Kumar
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function.
The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose,
AntriaBio announced the dosing of the first patient in their Phase 1 first-in-human clinical trial of its lead product candidate, AB101.
